BPC-157 / TB-500 tissue-repair research blend
BPC-157 / TB-500 Blend
Research blend of BPC-157 + TB-500 supplied as a lyophilized single-vial preparation (5/5 mg or 10/10 mg vial sizes)
Overview
The BPC-157 / TB-500 Blend is the tissue-repair power couple in a single vial. Both components are tissue-repair peptides, but they address different rate-limiting steps: BPC-157 drives vascular supply and fibroblast recruitment through VEGF-mediated angiogenesis and NO signalling; TB-500 drives cellular migration through actin polymerisation regulation that allows stem cells and repair cells to migrate to injury sites. Together they address the two most commonly rate-limiting layers of tissue repair — vascular supply and cellular movement — in a single reconstitution.
The blend is supplied in two vial sizes: 5/5 mg (10 mg total) and 10/10 mg (20 mg total). The 10/10 mg is the better practical choice — same concentration and per-injection dose but twice the supply per reconstitution. Fewer reconstitutions means better cold-chain management and less exposure to environmental degradation during storage.
Blend-specific human trial evidence does not exist. Component-level evidence supports each peptide individually — see the BPC-157 page (particularly Chang 2011 tendon-repair and Seiwerth 2019 review) and the TB-500 / thymosin β4 literature. The blend inherits the biology of its components; consumers should not import combination-specific clinical validation from single-peptide evidence.
Quick Facts & Evidence
- Category
- BPC-157 / TB-500 tissue-repair research blend
- Research area
- Research blend
- Most studied for
- Musculoskeletal injury (acute and maintenance)
- Tendon and ligament repair
- General tissue-repair support
- Recovery and resilience
- Clinical status
- Research use only — no approved clinical indication
- Human evidence
- Preclinical Evidence
- Regulatory status
- Not approved by FDA, EMA or MHRA
Preclinical Evidence
Data are from animal models, cell studies, or anecdotal community reports. No controlled human evidence.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format (two-component blend)
This page covers the RUO lyophilized BPC-157 + TB-500 blend vial reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention. The Snapshot uses the 10/10 mg vial size (Guide pro-tip preferred choice: same concentration and per-injection dose as the 5/5 mg, but 4 weeks of supply per reconstitution instead of 2).
BPC-157 / TB-500 Blend research values at a glance (10/10 mg vial).
| Item | Example value |
|---|---|
| Vial size | 20 mg total (BPC-157 10 mg + TB-500 10 mg); 5/5 mg = 10 mg total alternative |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 4.0 mL (10/10 mg vial); 2.0 mL (5/5 mg vial) |
| Final concentration (each ingredient) | 2.5 mg/mL of BPC-157 and 2.5 mg/mL of TB-500 |
| How it's given | Subcutaneous injection |
| Research dose | 0.5 mg of each ingredient per injection (= 20 units) |
| Frequency (acute) | 5× per week |
| Frequency (maintenance) | 3× per week |
| Cycling | Injury-duration driven — loading through acute phase, then maintenance. Not calendar-fixed. |
Reported Dosing
The practitioner-reference research protocol is 0.5 mg of each ingredient per injection (20 units), 5× per week during an acute injury phase and stepping down to 3× per week for maintenance. Duration is injury-driven rather than calendar-fixed. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 0.5 mg each (BPC-157 + TB-500) | 5× per week, subcutaneous | Acute injury phase; loading through the acute healing window | 0.2 mL at 2.5 mg/mL each; single injection delivers both |
| 0.5 mg each (BPC-157 + TB-500) | 3× per week, subcutaneous | Maintenance; step down once acute-phase healing has stabilised | Same volume; reduced cadence |
Why protocols vary
The two ingredients act on complementary but non-overlapping repair layers — BPC-157 drives vascular supply and fibroblast recruitment (VEGF-mediated), TB-500 drives cellular migration (actin polymerisation) — so a single volume delivers both without dose-splitting adjustments.
The Guide flags that TB-500 at blend dosing is a maintenance-level dose, not the loading-level dose used when TB-500 is run as a standalone loading protocol (2.5–5 mg twice weekly). Users seeking full TB-500 loading dose the individual TB-500 vial in parallel rather than relying on the blend.
The acute → maintenance cadence follows the injury-repair curve rather than a fixed calendar cycle; the Guide is explicit that this blend is not calendar-cycled.
Preparing the Solution
Turning the freeze-dried blend into a measurable liquid.
Blend composition
20 mg total peptide (BPC-157 10 mg + TB-500 10 mg)
The vial holds two lyophilized peptides in the same cake. Reconstituting with 4.0 mL of bacteriostatic water dissolves both at once and gives 2.5 mg/mL of each ingredient; a single injection volume delivers both in parallel.
BPC-157
- Mass in vial
- 10 mg
- Share of total
- 50%
- Concentration after mixing
- 2.5 mg/mL
- Reported per-injection dose
- 0.5 mg per injection
TB-500
- Mass in vial
- 10 mg
- Share of total
- 50%
- Concentration after mixing
- 2.5 mg/mL
- Reported per-injection dose
- 0.5 mg per injection
One reconstitution, one injection volume — both ingredients arrive together. The 5/5 mg vial is chemically equivalent (2.0 mL BAC → 2.5 mg/mL each) but gives only 2 weeks of supply per reconstitution; the Guide pro-tip prefers 10/10 mg for cold-chain reasons.
Documented in the practitioner reference (chapter 27)
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 20 mg blend vial (10 mg BPC-157 + 10 mg TB-500)
Diluent: 4.0 mL bacteriostatic water
Final concentration: 5 mg/mL total (2.5 mg/mL each)
Vial and volume from the practitioner reference; concentration calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
4mL
Resulting concentration
5 mg/mL
Equivalent volume
The reported research amount of 1 mg is contained within
0.2mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 20 mg ÷ 4 mL = 5 mg/mL
- Bacteriostatic water to match the documented concentration
- 20 mg ÷ 5 mg/mL = 4 mL
- Equivalent volume at this concentration
- 1 mg ÷ 5 mg/mL = 0.2 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner reference (10/10 mg vial variant); dose = 0.5 mg of each ingredient = 1 mg total per injectionResearch-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO blend preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, 5× per week (acute) or 3× per week (maintenance)
Documented in the practitioner reference · Research-practitioner guide
Why this method
Both BPC-157 and TB-500 are short peptides that would be degraded by gastrointestinal proteolysis; the subcutaneous route delivers them into circulation intact.
Systemic subcutaneous dosing is used because the mechanism relies on tissue-wide cellular signalling to reach injury sites throughout the body, not on a localised depot.
Injection sites reported
- Abdomen (rotate sites)
- Front of the thigh
- Back of the upper arm
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light
- Do not freeze
General RUO practice · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within the 4-week vial supply (10/10 mg) or 2 weeks (5/5 mg)
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice; supply-window per practitioner reference · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises standard RUO peptide handling. The 10/10 mg vial size is the practitioner-preferred choice for cold-chain reasons — fewer reconstitutions per unit of supply reduces environmental exposure.
Common Cycle
The practitioner reference frames the BPC-157 / TB-500 blend as injury-duration driven — a loading phase through the acute repair window, then maintenance for as long as the injury requires. It is not calendar-cycled.
- Cycle Length
- Acute phase 5×/week; maintenance 3×/week
- Break Before the Next Cycle
- Not calendar-cycled; stop when the injury has resolved
- What the Research Shows
- No blend-specific controlled follow-up trial exists; individual-component trials run 4–24 weeks
Documented in the practitioner reference; individual-component literature · Research-practitioner guide
TB-500 (the 17-amino-acid fragment used in this blend) is separately WADA-prohibited in athletes; blend use inherits this restriction.
Compound Overview
Current areas of research
Component-level effects and grey-market experience.
- Meaningful repair acceleration in acute musculoskeletal injury contexts
- Ongoing recovery and resilience support at maintenance dosing
- Combined vascular supply (BPC-157) and cellular migration (TB-500)
- Simpler protocol than running two separate peptides in parallel
Mechanism of action
The BPC-157 / TB-500 Blend is the tissue-repair power couple in a single vial. Both components are tissue-repair peptides, but they address different rate-limiting steps: BPC-157 drives vascular supply and fibroblast recruitment through VEGF-mediated angiogenesis and NO signalling; TB-500 drives cellular migration through actin polymerisation regulation that allows stem cells and repair cells to migrate to injury sites. Together they address the two most commonly rate-limiting layers of tissue repair — vascular supply and cellular movement — in a single reconstitution.
The blend is supplied in two vial sizes: 5/5 mg (10 mg total) and 10/10 mg (20 mg total). The 10/10 mg is the better practical choice — same concentration and per-injection dose but twice the supply per reconstitution. Fewer reconstitutions means better cold-chain management and less exposure to environmental degradation during storage.
Blend-specific human trial evidence does not exist. Component-level evidence supports each peptide individually — see the BPC-157 page (particularly Chang 2011 tendon-repair and Seiwerth 2019 review) and the TB-500 / thymosin β4 literature. The blend inherits the biology of its components; consumers should not import combination-specific clinical validation from single-peptide evidence.
- Two-component tissue-repair blend: BPC-157 + TB-500 in 1:1 ratio (5/5 mg or 10/10 mg vial sizes)
- 10/10 mg vial is the better practical choice — 4-week supply vs 2 with the same per-injection dose
- No blend-specific clinical trial evidence; component-level evidence supports each peptide individually
Human research
Component-level evidence is where the science lives: BPC-157 (Chang 2011 tendon repair, Seiwerth 2019 consolidating review, Sikiric 2010 broader framework) and TB-500 / thymosin β4 (the Goldstein tradition of thymosin peptide research).
Chang 2011 BPC-157 tendon
The BPC-157 tendon-repair paper — foundation for the BPC-157 component.
Seiwerth 2019 BPC-157 review
Consolidating review of the BPC-157 evidence base.
Sikiric 2010 BPC-157
Broader BPC-157 framework.
Goldstein 1972 (thymosin discovery)
Discovery of the thymosin family (parent of TB-500).
No blend regulatory authorisation. Neither component is FDA-approved. BPC-157 is on the WADA prohibited list.
No blend-specific human trial has been published.
Safety considerations
Component-level and grey-market experience.
- Mild injection-site reactions
- Generally excellent tolerability
- Component-level side effects apply — see the BPC-157 and TB-500 pages
Component-level warnings apply.
- Active or recent malignancy — both components pro-angiogenic
- Pregnancy and breastfeeding
- Hypersensitivity to either component
- BPC-157 WADA prohibited-list — this applies to any BPC-157-containing blend
Monitoring
- Injection-site reactions
- Injury endpoint response
- Systemic tolerability
Frequently asked questions
Which vial size should I choose?
The 10/10 mg vial is the better practical choice. Both vial sizes deliver the same 0.5 mg per component per 0.2 mL injection, but the 10/10 mg vial provides a 4-week supply vs 2 for the 5/5 mg — half as many reconstitutions across the same use window, better cold-chain management, less exposure to environmental degradation during storage.
How is this different from running the peptides separately?
Pharmacologically the same. The difference is convenience — one reconstitution, one injection, both components delivered together. What you cannot do with the blend that you can with separate vials is titrate the two components independently (e.g. front-load TB-500 and lower BPC-157, or vice versa). For most use cases the convenience outweighs the flexibility loss.
Is this appropriate for acute musculoskeletal injury?
At 0.2 mL delivering 0.5 mg of each component × 5 injections per week, TB-500 exposure is 2.5 mg/week — approximately half of the acute-injury full loading standard (5 mg/week). For serious acute injury requiring full TB-500 loading, supplemental TB-500 dosing during the loading phase should be considered. For maintenance recovery and most chronic contexts, the blend dose is at appropriate levels.
Does the blend inherit the BPC-157 WADA prohibition?
Yes. BPC-157 is on the WADA prohibited list under S0 (non-approved substances). Any BPC-157-containing blend inherits this prohibition. Competitive athletes should not use this blend.
Is there evidence for the specific combination?
No randomised placebo-controlled trial has evaluated the specific BPC-157 + TB-500 combination as a single product. Component-level evidence (see the individual pages) supports each peptide but does not automatically constitute evidence for the combination. The mechanistic rationale is coherent; the combination-specific clinical validation is not there.
References
- [1]
BPC 157 and Standard Angiogenic Growth Factors — Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing — Seiwerth S, Milavic M, Vukojevic J, et al., Frontiers in Pharmacology (2019)
- [2]
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS, Journal of Applied Physiology (2011)
- [3]
Isolation of a biologically active fraction from bovine thymus (thymosin fraction 5) — the discovery paper for the thymosin peptide family — Goldstein AL, Guha A, Zatz MM, Hardy MA, White A, Proceedings of the National Academy of Sciences (1972)
- [4]
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract — Sikiric P, Seiwerth S, Rucman R, et al., Current Pharmaceutical Design (2010)
- [5]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.
Related on Healthy Mango
Categories